GLP 2 Human
GLP2, GLP-2, GLP 2.
Description
GLP-2 contains 34 amino acids having a molecular mass of 3922.38 Dalton.
Product Specs
GLP2, GLP-2, GLP 2.
Product Science Overview
Human Glucagon-Like Peptide-2 (GLP-2) is a 33-amino acid peptide hormone derived from the proglucagon gene. It is produced by the intestinal enteroendocrine L cells and certain neurons in the central nervous system . GLP-2 plays a crucial role in regulating various aspects of intestinal physiology, including nutrient absorption, intestinal growth, and maintenance of the gut barrier function .
GLP-2 was first identified in the early 1990s as a product of the post-translational processing of proglucagon, a precursor protein that also gives rise to other important peptides such as glucagon and GLP-1 . The sequence of GLP-2 is encoded carboxyterminal to GLP-1 in the proglucagon gene . The peptide is co-secreted with GLP-1 in response to nutrient ingestion .
GLP-2 exerts its effects primarily through the GLP-2 receptor (GLP-2R), a G protein-coupled receptor expressed in various tissues, including the gut . The primary functions of GLP-2 include:
- Intestinal Growth and Repair: GLP-2 stimulates the growth of the intestinal mucosa by increasing crypt cell proliferation and decreasing enterocyte apoptosis. This leads to an increase in villus height and overall intestinal surface area, enhancing nutrient absorption .
- Gut Barrier Function: GLP-2 enhances the barrier function of the gut epithelium, reducing intestinal permeability and protecting against bacterial translocation .
- Regulation of Gastric Motility and Secretion: GLP-2 slows gastric emptying and reduces gastric acid secretion, contributing to improved nutrient absorption and digestion .
GLP-2 and its analogs have been explored for their therapeutic potential in various gastrointestinal disorders. One of the most notable applications is in the treatment of short bowel syndrome (SBS), a condition characterized by malabsorption due to the surgical removal or congenital absence of a significant portion of the small intestine . GLP-2 analogs, such as teduglutide, have been shown to improve intestinal absorption and reduce the need for parenteral nutrition in SBS patients .
